NeuroQuest

NeuroQuest is a private Israeli-US biotechnology diagnostics company developing NeuroScreen, a blood-based test for early detection and monitoring of Alzheimer's disease. Its approach uses peripheral immune blood-cell biomarkers together with a proprietary algorithm to predict brain amyloid-beta burden, including in asymptomatic individuals. The company positions the assay as a lower-cost, less invasive alternative or complement to PET imaging and cerebrospinal fluid testing for identifying patients earlier in the disease course. NeuroQuest has reported clinical research collaborations with AIBL in Australia and is conducting US validation work through its South Carolina development center to support FDA submission. The company appears focused on commercialization of a single lead diagnostic program rather than a broad therapeutic pipeline.